Abstract
Glioblastoma is resistant to conventional treatments and has dismal prognosis. Despite promising in vitro data, molecular targeted agents have failed to improve outcomes in patients, indicating that conventional two-dimensional (2D) in vitro models of GBM do not recapitulate the clinical scenario. Responses of primary glioblastoma stem-like cells (GSC) to radiation in combination with EGFR, VEGF, and Akt inhibition were investigated in conventional 2D cultures and a three-dimensional (3D) in vitro model of GBM that recapitulates key GBM clinical features. VEGF deprivation had no effect on radiation responses of 2D GSCs, but enhanced radiosensitivity of GSC cultures in 3D. The opposite effects were observed for EGFR inhibition. Detailed analysis of VEGF and EGF signaling demonstrated a radioprotective role of Akt that correlates with VEGF in 3D and with EGFR in 2D. In all cases, positive correlations were observed between increased radiosensitivity, markers of unrepaired DNA damage and persistent phospho-DNA-PK nuclear foci. Conversely, increased numbers of Rad51 foci were observed in radioresistant populations, indicating a novel role for VEGF/Akt signaling in influencing radiosensitivity by regulating the balance between nonhomologous end-joining and homologous recombination–mediated DNA repair. Differential activation of tyrosine kinase receptors in 2D and 3D models of GBM explains the well documented discrepancy between preclinical and clinical effects of EGFR inhibitors. Data obtained from our 3D model identify novel determinants and mechanisms of DNA repair and radiosensitivity in GBM, and confirm Akt as a promising therapeutic target in this cancer of unmet need.
| Original language | English |
|---|---|
| Pages (from-to) | 575-589 |
| Number of pages | 15 |
| Journal | Molecular Cancer Therapeutics |
| Volume | 19 |
| Issue number | 2 |
| Early online date | 31 Oct 2019 |
| DOIs | |
| Publication status | Published - 29 Feb 2020 |
Funding
S.A. Dongre reports receiving a commercial research grant from AstraZeneca. A.J. Chalmers reports receiving a commercial research grant and is a consultant/advisory board member for AstraZeneca. No potential conflicts of interest were disclosed. Cell lines were kindly donated by Dr. Colin Watts (University of Cambridge, Cambridge, United Kingdom). This research was funded by a Chief Scientist Office (CSO, grant number ETM/405; to A. Chalmers). We also thank the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) for funding this work (grant no. NC/P001335/1; to A. Chalmers and N. Gomez-Roman).
Keywords
- glioblastoma
- three-dimensional
- DNA repair
- VEGF
- EGFR
- erlotinib
- DNA-PKcs
- HR
- NHEJ
- 2D
Fingerprint
Dive into the research topics of 'Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver